Visual Function Benefit After Treatment With Pegcetacoplan: Microperimetry Analysis From The Phase 3 Oaks Trial: Microperimetry: Visual Function Benefit With Pegcetacoplan

Macular Diseases

Visual Acuity and Quality of Life Outcomes with Pegcetacoplan Treatment: A Post Hoc Analysis from the OAKS and DERBY Trials

Am J Ophthalmol

Chiang A, Davis M, Stevens W, Garg S, Sheidow T, Jones DL, Intorcia M, McKeown A, Schmidt-Erfurth UM, Sarda SP, Baumal CR

doi: 10.1016/j.ajo.2025.05.023

Macular Diseases

Efficacy and Safety of Ranibizumab Biosimilar QL1205 in Neovascular Age-related Macular Degeneration: A Phase 3 Randomized Trial

Ophthalmol Retina

Hamouz J, Nowosielska A, Święch-Zubilewicz A, Abengoechea S, Baumane K, Vajas A, Siewierska M, Veselovsky M, Veith M, Kerényi Á, Mange S, Baidya K, Laganovska G, Jürgens I, Papp A, Gosai J, Štefanickova J, Han M, Fryczkowski P, Zalewski D, Wang J, Wei W

doi: 10.1016/j.oret.2024.10.001

Further Publications

3-year results of 0.01% and 0.1% loading dose atropine treatment including washout in Danish children with myopia: a placebo-controlled, randomised clinical trial

Br J Ophthalmol

Hansen N, Hvid-Hansen A, Møller F, Bek T, Larsen D, Jacobsen N, Kessel L

doi: 10.1136/bjo-2024-326918

Blindness and Vision Impairment

Visual outcome including visual field defects after treatment of paediatric optic pathway glioma: A nationwide cohort study

Acta Ophthalmol

Bennebroek CAM, van Zwol J, Montauban van Swijndregt MC, Loudon SE, Groot ALW, Bauer NJC, Pott JW, Notting IC, van Sorge AJ, van Genderen MM, de Graaf P, Schouten-van Meeteren AYN, Saeed P, Porro GL

doi: 10.1111/aos.17476

Macular Diseases

Disease activity and therapeutic response to pegcetacoplan for geographic atrophy identified by deep learning-based analysis of OCT

Ophthalmology

Schmidt-Erfurth U, Mai J, Reiter GS, Riedl S, Vogl WD, Sadeghipour A, McKeown A, Foos E, Scheibler L, Bogunovic H

doi: 10.1016/j.ophtha.2024.08.017

Retinal Diseases

Clinical characteristics associated with complications and poor visual outcomes in ocular toxoplasmosis: Analysis of 853 patients: complications and visual outcomes in ocular toxoplasmosis

Am J Ophthalmol

de-la-Torre A, Mejía-Salgado G, Cifuentes-González C, Cuevas M, García S, Rangel CM, Durán C, Pachón-Suárez DI, Bustamante-Arias A, Rojas-Carabali W

doi: 10.1016/j.ajo.2025.02.027

Macular Diseases

Comparison of treatment routine using aflibercept: Strict vs. relaxed retreatment regimen (TOLERANT study)-A non-inferiority, randomized controlled trial

Acta Ophthalmol

Jaggi D, Berger LE, Zweifel S, Becker MD, Michels S, Stalder O, Lincke JB, Habra O, Wolf S, Zinkernagel MS

doi: 10.1111/aos.17514

Glaucoma and Ocular PressureSurgery and Intervention

The Impact of Baseline Intraocular Pressure on Initial Treatment Response in the LiGHT Trial: Selective Laser Trabeculoplasty versus Medication

Ophthalmology

Fahy ET, Montesano G, Garg A, Vickerstaff V, Konstantakopoulou E, Gazzard G, LiGHT Trial Study Group

doi: 10.1016/j.ophtha.2024.06.022

Macular Diseases

Anatomic Outcomes With Faricimab vs. Aflibercept in the Head-to-Head Dosing Phase of the TENAYA/LUCERNE Trials in Neovascular AMD

Ophthalmology

Gemmy Cheung CM, Lim JI, Priglinger S, Querques G, Margaron P, Patel S, Souverain A, Willis JR, Yang M, Guymer R

doi: 10.1016/j.ophtha.2024.11.023

Related content

Visual Acuity and Quality of Life Outcomes with Pegcetacoplan Treatment: A Post Hoc Analysis from the OAKS and DERBY Trials

Efficacy and Safety of Ranibizumab Biosimilar QL1205 in Neovascular Age-related Macular Degeneration: A Phase 3 Randomized Trial

3-year results of 0.01% and 0.1% loading dose atropine treatment including washout in Danish children with myopia: a placebo-controlled, randomised clinical trial

Visual outcome including visual field defects after treatment of paediatric optic pathway glioma: A nationwide cohort study

Disease activity and therapeutic response to pegcetacoplan for geographic atrophy identified by deep learning-based analysis of OCT

Clinical characteristics associated with complications and poor visual outcomes in ocular toxoplasmosis: Analysis of 853 patients: complications and visual outcomes in ocular toxoplasmosis

Comparison of treatment routine using aflibercept: Strict vs. relaxed retreatment regimen (TOLERANT study)-A non-inferiority, randomized controlled trial

The Impact of Baseline Intraocular Pressure on Initial Treatment Response in the LiGHT Trial: Selective Laser Trabeculoplasty versus Medication

Anatomic Outcomes With Faricimab vs. Aflibercept in the Head-to-Head Dosing Phase of the TENAYA/LUCERNE Trials in Neovascular AMD